Safety of prolonged wait time for gastrectomy in clinical stage I gastric cancer

Keiichi Fujiya, Tomoyuki Irino, Kenichiro Furukawa, Hayato Omori, Rie Makuuchi, Yutaka Tanizawa, Etsuro Bando, Masanori Terashima

Research output: Contribution to journalArticle

Abstract

Background: Patients with stage I gastric cancer tend to wait for surgery. Although the cancer may progress during such a delay, effects of wait time for surgery on survival remain inconsistent. Here, we evaluated the safety of surgical wait time on survival of patients with clinical stage I gastric cancer. Methods: The outcomes of 556 patients who underwent gastrectomy for clinical stage I gastric cancer between January 2007 and December 2011 were retrospectively evaluated. Patients were stratified into three groups based on wait time: short- (<61 days, n = 185), intermediate- (61–90 days, n = 218), and long-wait (91–180 days, n = 153) groups. Clinicopathological findings and survival were compared among the groups. Results: The median wait time was 72 days. Age and comorbidities differed among the groups, but clinical and pathological cancer stages did not. Overall survival was comparable; the 5-year overall survival was 90.2%, 93.6%, and 88.8% in the short-, intermediate-, and long-wait groups, respectively. Multivariate analysis revealed that wait time was not an independent prognostic factor for overall survival. Adjusted hazard ratios (HRs) were 0.69 (p = 0.262) and 1.03 (p = 0.926) in the intermediate- and long-wait groups, respectively, with short wait time as the reference. Relapse-free survival was comparable among the groups (intermediate-wait HR = 0.80, p = 0.476; long-wait HR = 1.10, p = 0.740). Conclusion: A half-year wait time for surgery was not independently associated with survival of patients with clinical stage I gastric cancer and may therefore be acceptable.

Original languageEnglish
JournalEuropean Journal of Surgical Oncology
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Gastrectomy
Stomach Neoplasms
Safety
Survival
Comorbidity
Neoplasms
Multivariate Analysis
Recurrence

Keywords

  • Comorbidity
  • Elderly
  • Endoscopy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Fujiya, K., Irino, T., Furukawa, K., Omori, H., Makuuchi, R., Tanizawa, Y., ... Terashima, M. (2019). Safety of prolonged wait time for gastrectomy in clinical stage I gastric cancer. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2019.06.006

Safety of prolonged wait time for gastrectomy in clinical stage I gastric cancer. / Fujiya, Keiichi; Irino, Tomoyuki; Furukawa, Kenichiro; Omori, Hayato; Makuuchi, Rie; Tanizawa, Yutaka; Bando, Etsuro; Terashima, Masanori.

In: European Journal of Surgical Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Fujiya, K, Irino, T, Furukawa, K, Omori, H, Makuuchi, R, Tanizawa, Y, Bando, E & Terashima, M 2019, 'Safety of prolonged wait time for gastrectomy in clinical stage I gastric cancer', European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2019.06.006
Fujiya, Keiichi ; Irino, Tomoyuki ; Furukawa, Kenichiro ; Omori, Hayato ; Makuuchi, Rie ; Tanizawa, Yutaka ; Bando, Etsuro ; Terashima, Masanori. / Safety of prolonged wait time for gastrectomy in clinical stage I gastric cancer. In: European Journal of Surgical Oncology. 2019.
@article{3402797fe62842b395bfb39a49b9b268,
title = "Safety of prolonged wait time for gastrectomy in clinical stage I gastric cancer",
abstract = "Background: Patients with stage I gastric cancer tend to wait for surgery. Although the cancer may progress during such a delay, effects of wait time for surgery on survival remain inconsistent. Here, we evaluated the safety of surgical wait time on survival of patients with clinical stage I gastric cancer. Methods: The outcomes of 556 patients who underwent gastrectomy for clinical stage I gastric cancer between January 2007 and December 2011 were retrospectively evaluated. Patients were stratified into three groups based on wait time: short- (<61 days, n = 185), intermediate- (61–90 days, n = 218), and long-wait (91–180 days, n = 153) groups. Clinicopathological findings and survival were compared among the groups. Results: The median wait time was 72 days. Age and comorbidities differed among the groups, but clinical and pathological cancer stages did not. Overall survival was comparable; the 5-year overall survival was 90.2{\%}, 93.6{\%}, and 88.8{\%} in the short-, intermediate-, and long-wait groups, respectively. Multivariate analysis revealed that wait time was not an independent prognostic factor for overall survival. Adjusted hazard ratios (HRs) were 0.69 (p = 0.262) and 1.03 (p = 0.926) in the intermediate- and long-wait groups, respectively, with short wait time as the reference. Relapse-free survival was comparable among the groups (intermediate-wait HR = 0.80, p = 0.476; long-wait HR = 1.10, p = 0.740). Conclusion: A half-year wait time for surgery was not independently associated with survival of patients with clinical stage I gastric cancer and may therefore be acceptable.",
keywords = "Comorbidity, Elderly, Endoscopy",
author = "Keiichi Fujiya and Tomoyuki Irino and Kenichiro Furukawa and Hayato Omori and Rie Makuuchi and Yutaka Tanizawa and Etsuro Bando and Masanori Terashima",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ejso.2019.06.006",
language = "English",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Safety of prolonged wait time for gastrectomy in clinical stage I gastric cancer

AU - Fujiya, Keiichi

AU - Irino, Tomoyuki

AU - Furukawa, Kenichiro

AU - Omori, Hayato

AU - Makuuchi, Rie

AU - Tanizawa, Yutaka

AU - Bando, Etsuro

AU - Terashima, Masanori

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Patients with stage I gastric cancer tend to wait for surgery. Although the cancer may progress during such a delay, effects of wait time for surgery on survival remain inconsistent. Here, we evaluated the safety of surgical wait time on survival of patients with clinical stage I gastric cancer. Methods: The outcomes of 556 patients who underwent gastrectomy for clinical stage I gastric cancer between January 2007 and December 2011 were retrospectively evaluated. Patients were stratified into three groups based on wait time: short- (<61 days, n = 185), intermediate- (61–90 days, n = 218), and long-wait (91–180 days, n = 153) groups. Clinicopathological findings and survival were compared among the groups. Results: The median wait time was 72 days. Age and comorbidities differed among the groups, but clinical and pathological cancer stages did not. Overall survival was comparable; the 5-year overall survival was 90.2%, 93.6%, and 88.8% in the short-, intermediate-, and long-wait groups, respectively. Multivariate analysis revealed that wait time was not an independent prognostic factor for overall survival. Adjusted hazard ratios (HRs) were 0.69 (p = 0.262) and 1.03 (p = 0.926) in the intermediate- and long-wait groups, respectively, with short wait time as the reference. Relapse-free survival was comparable among the groups (intermediate-wait HR = 0.80, p = 0.476; long-wait HR = 1.10, p = 0.740). Conclusion: A half-year wait time for surgery was not independently associated with survival of patients with clinical stage I gastric cancer and may therefore be acceptable.

AB - Background: Patients with stage I gastric cancer tend to wait for surgery. Although the cancer may progress during such a delay, effects of wait time for surgery on survival remain inconsistent. Here, we evaluated the safety of surgical wait time on survival of patients with clinical stage I gastric cancer. Methods: The outcomes of 556 patients who underwent gastrectomy for clinical stage I gastric cancer between January 2007 and December 2011 were retrospectively evaluated. Patients were stratified into three groups based on wait time: short- (<61 days, n = 185), intermediate- (61–90 days, n = 218), and long-wait (91–180 days, n = 153) groups. Clinicopathological findings and survival were compared among the groups. Results: The median wait time was 72 days. Age and comorbidities differed among the groups, but clinical and pathological cancer stages did not. Overall survival was comparable; the 5-year overall survival was 90.2%, 93.6%, and 88.8% in the short-, intermediate-, and long-wait groups, respectively. Multivariate analysis revealed that wait time was not an independent prognostic factor for overall survival. Adjusted hazard ratios (HRs) were 0.69 (p = 0.262) and 1.03 (p = 0.926) in the intermediate- and long-wait groups, respectively, with short wait time as the reference. Relapse-free survival was comparable among the groups (intermediate-wait HR = 0.80, p = 0.476; long-wait HR = 1.10, p = 0.740). Conclusion: A half-year wait time for surgery was not independently associated with survival of patients with clinical stage I gastric cancer and may therefore be acceptable.

KW - Comorbidity

KW - Elderly

KW - Endoscopy

UR - http://www.scopus.com/inward/record.url?scp=85067422849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067422849&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2019.06.006

DO - 10.1016/j.ejso.2019.06.006

M3 - Article

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

ER -